@Optimi_Health

Optimi is a commercial-stage pharmaceutical company manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. $OPTH

 Canada
optimi.net/
Joined April 2021
  • Tweets862
  • Following423
  • Followers927
359Media
👀🍄✈️ @MindMedicineAU
Corey Tochor
@ctochorJul 16
Currently in Canada we're growing the mushrooms, we're extracting the psilocybin, and shipping it across the world, but our physicians can't prescribe it. This makes no sense at all!  Please sign my petition supporting Thomas' Bill: thomasbill.ca/petition
5
1,144
Two years ago the FDA rejected the first psychedelic therapy for PTSD. Today the US government is openly asking how it can get these treatments to millions of veterans as quickly as possible. That is a remarkable shift, and in my view it is not mainly about politics. It is about the fact that conventional psychiatry has very little to offer people with severe PTSD or treatment-resistant depression. Many veterans did not wait for Washington. They travelled to Mexico, got treated and came back with stories that were impossible to ignore. The brain is the last great frontier in medicine. Psychedelics are one of the first tools that actually change how it works, rather than just managing symptoms. Article in the comments.
2
2
19
390
Optimi Health CEO and Co-Founder Dane Stevens comments on the establishment of Optimi Australia, a new wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across the country. For details: bit.ly/4jHuV3Q $OPTH
1
1
69
Optimi Health announced the establishment of Optimi Australia Pty Ltd, a wholly owned subsidiary responsible for distribution and business development in Australia, and the appointment of Adrian Jones as Director of Australian Operations. bit.ly/4jHuV3Q $OPTH
1
1
63
Since President Trump's psychedelics-focused Executive Order in April, a slew of federal agencies and departments have engaged in related activities: from funding psychedelic research through to public hearings and requests for information.
1
7
32
1,177
Producing botanical psilocybin for regulated programs requires control across cultivation, processing, testing and finished dosage form manufacturing. Optimi manages these stages at its Princeton facility to support consistency and quality throughout the process.
1
1
6
123
New episode: Peaking director Jordan Kronick on taking cameras into the dosing room across six psychedelics, the 2004 doc that helped reopen MDMA research, and psychedelics for brain injury in pro sports. bit.ly/pt662-peaking

From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics

Peaking director Jordan Kronick on filming psychedelic healing in the dosing room, Ecstasy Rising, brain injury in sports, and the drug war.

psychedelicstoday.com
1
3
9
848
$OPTH CEO Dane Stevens comments on the completion of the Company's latest MDMA finished drug product batch, expected to supply the proposed Phase 3 PTSD trial in Canada, a planned 2026 export to Australia, & a previously announced trial in Israel with MAPS. bit.ly/4ie9Xap
1
4
151
Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories: • Early Notes from The Psychedelic Healthcare Forum • FDA Floats an Ibogaine Trial Design, Asks Field for Input • Compass Talks Pricing, Label and a Slow Launch • New Mexico Nears Medical Psilocybin Launch • Six More Potential Psychedelic Brand Names Listen on our website or on your favourite podcast app: psychedelicalpha.com/news/po…
1
1
4
1,250
$OPTH announced the completion of its latest production batch of MDMA finished drug product, expected to supply the proposed Phase 3 PTSD trial in Canada, a planned 2026 commercial export to Australia, & a previously announced clinical trial in Israel with @MAPS. bit.ly/4ie9Xap
1
1
4
184
As psychedelic treatments approach potential FDA approval, psychiatrists need to be ready for patients’ questions. To help prepare them, Johns Hopkins, Yale, NYU, and Columbia developed a standardized psychedelic medicine curriculum for psychiatry trainees. The first multi-site evaluation of the course was just published in Academic Psychiatry. After the course: 💡 Confidence counseling patients about clinical research and legal care nearly doubled 🔬 Understanding of the limitations of current evidence rose sharply 📈 Knowledge quiz scores improved ⚖️ Trainees gained a more balanced, critically informed view of the evidence, without inflated enthusiasm for the field We’re continuing to develop educational and training programs for professionals across a range of fields, so stay tuned! doi.org/10.1007/s40596-026-0…
7
11
1
68
3,943
See our new paper on Psilocybin for Anhedonia in Unipolar and Bipolar Depression sciencedirect.com/science/ar…
1
7
20
1,065
Progress starts long before a treatment reaches a patient. It takes careful preparation, consistent processes, and people committed to getting the details right. That work is central to our approach at Optimi. #OptimiHealth #LifeSciences
1
2
106
Sounding the alarm - if MDMA & psilocybin are approved by FDA, most MDMA & psilocybin could still be scheduled I, wildly inconsistent with the science. @Ravarora1 & I lay out the case for why we need to avoid a "bifurcated schedule" that only reschedules the commercial FDA approved product. Please repost & spread the word! illusionconsensus.com/p/psyc…

Psychedelics Could Remain Schedule I Drugs Even if FDA Approved as Medicines

What Many Psychedelic Medicine Supporters Don’t Know, and How the Feds Can Do It Right.

illusionconsensus.com
20
45
14
175
24,693
Reminder: Optimi Health will present a corporate overview at the ThinkEquity Conference on October 15, at 4:00 p.m. ET, at the Mandarin Oriental Hotel in New York City. For more information and to register for the conference, visit: bit.ly/4hK19sx $OPTH
4
183
At Optimi’s Princeton, British Columbia facility, cultivation and laboratory work are carried out as part of one vertically integrated operation. $OPTH
1
1
66
Replying to @Optimi_Health
There hasn’t been anything new developed in the past 4 decades to treat mental health issues from anxiety to OCD to depression to bipolar disorder. Finally there is something new that is proven to help. Hope the USA takes the lead here and now and gets these drugs developed.
1
2
33
Psychedelic medicine is approaching a turning point. In a new Fortune commentary, Optimi Health CEO and Co-Founder Dane Stevens explains why the U.S. needs the right infrastructure to support regulated access. Read more: fortune.com/2026/10/12/psych…

Psychedelic medicine is approaching a turning point. The U.S. needs the right infrastructure to be...

Today’s psychedelics bear little resemblance to 1970s counterparts. These medicines undergo rigorous clinical trials and licensed manufacturing processes.

fortune.com
1
1
1
9
323
Consistency in pharmaceutical manufacturing is built through routine: documented procedures, controlled environments, defined specifications and quality review. These systems guide the work at Optimi’s facility in Princeton, British Columbia.
1
6
218
Optimi retweeted
NBC News
@NBCNewsOct 11
As the Trump administration seeks to fast-track psychedelic drugs, the FDA could approve one for the first time early next year. But that possibility has brought up complicated questions about who should be allowed to administer the treatments and under what conditions. nbcnews.com/health/health-ne…

The FDA may soon approve its first psychedelic drug. But how to regulate it?

The agency plans to fast-track applications for several psychedelics, but it must also create a set of rules about who can take and administer them and in what settings.

nbcnews.com
22
34
4
107
34,347
#MDD and #PTSD are serious mental health conditions that can significantly impact daily life and overall well-being. This #WorldMentalHealthDay, $OPTH recognizes the continued need for expanded treatment options and remains committed to contributing to this important work. bit.ly/4yvmDAs
8
239
Load more